CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $16.44M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 11.03: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.12TKRW809.28M · vs all stocks (USD)
Revenue (TTM)
22.78BKRW16.44M · vs all stocks (USD)
Profit Margin
-23.26%vs Biotechnology peers
Beta
0.5920xvs all stocks
52-Week Change
38.30%vs all stocks
Market Capitalization
1.12TKRW809.28M · vs all stocks (USD)
Enterprise Value
1.12TKRW806.70M · vs all stocks (USD)
Price to Sales (TTM)
49.56xvs Biotechnology peers
Price to Book (MRQ)
10.88xvs Biotechnology peers
Enterprise to Revenue
49.06xvs Biotechnology peers
Enterprise to EBITDA
-87.65xvs Biotechnology peers
Gross Margin
42.98%vs Biotechnology peers
Profit Margin
-23.26%vs Biotechnology peers
Operating Margin
-65.97%vs Biotechnology peers
Return on Assets (TTM)
-8.26%vs Biotechnology peers
Return on Equity (TTM)
-7.44%vs Biotechnology peers
Revenue (TTM)
22.78BKRW16.44M · vs all stocks (USD)
Revenue per Share (TTM)
710.29KRWUpdated Sep 20, 2026Quarterly Revenue Growth
64.40%vs Biotechnology peers
Gross Profit (TTM)
5.74BKRW4.14M · vs all stocks (USD)
EBITDA (TTM)
-12.75BKRW-9.20M · vs all stocks (USD)
Net Income (TTM)
-5.30BKRW-3.82M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
64.43%vs Biotechnology peers
Operating Cash Flow (TTM)
-17.64BKRW-12.73M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-60.69BKRW-43.80M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
19.32BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
15.67BKRWFY2025 · Dec 31, 2025Gross Profit
3.65BKRWFY2025 · Dec 31, 2025Operating Income
-12.19BKRW-8.80M · vs all stocks (USD)
Pre-tax Income
-16.45BKRWFY2025 · Dec 31, 2025Net Income
-16.45BKRWFY2025 · Dec 31, 2025EBIT
-14.31BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-8.74BKRWFY2025 · Dec 31, 2025Research & Development
28.38MKRWFY2025 · Dec 31, 2025Selling, General & Administrative
5.54BKRWFY2025 · Dec 31, 2025Other Operating Expenses
-194.20MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
449.95MKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
2.14BKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
-16.45BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-15.90BKRWFY2025 · Dec 31, 2025Free Cash Flow
-58.52BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
40.43BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-16.45BKRWFY2025 · Dec 31, 2025Stock-based Compensation
1.46BKRWFY2025 · Dec 31, 2025Other Non-cash Items
1.44BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
177.55MKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.53BKRWFY2025 · Dec 31, 2025Capital Expenditures
-42.62BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-34.26MKRWFY2025 · Dec 31, 2025Sale of Investments
9.46BKRWFY2025 · Dec 31, 2025Other Investing Activity
-187.66MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-33.35BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
39.43BKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-11.69BKRWFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-2.38BKRWFY2025 · Dec 31, 2025Other Financing Charges
12.06MKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
67.37BKRWFY2025 · Dec 31, 2025Shares Outstanding
34.50MSharesUpdated Sep 20, 2026Float Shares
23.76MSharesUpdated Sep 20, 2026% Held by Insiders
27.69%vs all stocks
% Held by Institutions
0.87%vs all stocks
Total Cash (MRQ)
72.23BKRW52.13M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.08KKRWUpdated Sep 20, 2026Total Debt (MRQ)
63.59BKRW45.90M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.6144xvs Biotechnology peers
Current Ratio (MRQ)
1.55xvs Biotechnology peers
Book Value per Share (MRQ)
2.99KKRWUpdated Sep 20, 2026Total Assets
123.04BKRW88.81M · vs all stocks (USD)
Total Current Assets
54.99BKRWFY2025 · Dec 31, 2025Total Liabilities
54.44BKRWFY2025 · Dec 31, 2025Total Non-current Assets
68.04BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
6.37BKRWFY2025 · Dec 31, 2025Total Current Liabilities
48.08BKRWFY2025 · Dec 31, 2025Cash
287.00KKRWFY2025 · Dec 31, 2025Cash Equivalents
40.43BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
40.43BKRWFY2025 · Dec 31, 2025Accounts Receivable
2.47BKRWFY2025 · Dec 31, 2025Inventory
4.85BKRWFY2025 · Dec 31, 2025Accounts Payable
1.57BKRWFY2025 · Dec 31, 2025Short-term Debt
38.04BKRWFY2025 · Dec 31, 2025Other Current Liabilities
1.00KKRWFY2025 · Dec 31, 2025Long-term Debt
5.27BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
120.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
15.98BKRWFY2025 · Dec 31, 2025Retained Earnings
-102.57BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
68.59BKRW49.51M · vs all stocks (USD)
52-Week Low
13.86KKRWUpdated Sep 20, 202652-Week High
49.90KKRWUpdated Sep 20, 202652-Week Change
38.30%vs all stocks
Beta
0.5920xvs all stocks
50-Day MA
34.34KKRWUpdated Sep 20, 2026200-Day MA
32.83KKRWUpdated Sep 20, 2026Avg 10-Day Volume
208.14KSharesUpdated Sep 20, 2026Avg 30-Day Volume
175.64KSharesUpdated Sep 20, 2026Diluted EPS (TTM)
-601.00KRWUpdated Sep 20, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.43Profit Margin: -0.23
Financial Health
Altman Z-Score 11.03: safe zoneNotable
Altman Z-Score: 11.03
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $16.44M, lower than 95% of all stocks globallySignificant
Revenue (USD): 16,442,691.401Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Geron Corporation
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Jibeier Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Chunlizhengda Medical Instruments Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Keyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Lexicon Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Luoxin Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jacobio Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
4D Molecular Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Esperion Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
InMode Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Md Entertainment Tbk
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Beijing Xiaocheng Technology Co. Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated